Biocon Intrinsic Value
Biocon (BIOCON) median intrinsic value is ₹179.18 from 9 valuation models (range ₹125–₹903), vs current price ₹415.55 — -56.9% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit BIOCON share price.
BIOCON Valuation Methods Summary — DCF, Graham Number & P/E
Biocon intrinsic value across 9 models vs current price ₹415.55 — upside/downside and value range per method. Read BIOCON dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹124.66 | ₹99.73 - ₹149.59 | -70.0% | EPS: ₹3.16, Sector P/E: 22x |
| Book Value Method | asset | ₹903.13 | ₹812.82 - ₹993.44 | +117.3% | Book Value/Share: ₹451.57, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹447.55 | ₹402.80 - ₹492.31 | +7.7% | Revenue/Share: ₹223.77, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹473.49 | ₹426.14 - ₹520.84 | +13.9% | EBITDA: ₹3840.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹322.83 | ₹258.26 - ₹387.40 | -22.3% | CF Growth: 14.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹124.66 | ₹112.19 - ₹137.13 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹124.66 | ₹112.19 - ₹137.13 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹179.18 | ₹161.26 - ₹197.10 | -56.9% | EPS: ₹3.16, BVPS: ₹451.57 |
| Dividend Yield Method | dividend | ₹124.66 | ₹112.19 - ₹137.13 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
BIOCON Intrinsic Value vs Market Price — All Valuation Models
Biocon fair value range ₹125–₹903 vs current market price ₹415.55 across 9 valuation models. Compare with BIOCON fair price to assess whether the stock is under or overvalued.
BIOCON Intrinsic Value Analysis — Undervalued or Overvalued?
Biocon median intrinsic value ₹179.18, current price ₹415.55 — Trading Above Calculated Value by 56.9%, margin of safety -100.0%.
What is the intrinsic value of BIOCON?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Biocon (BIOCON) is ₹179.18 (median value). With the current market price of ₹415.55, this represents a -56.9% variance from our estimated fair value.
The valuation range spans from ₹124.66 to ₹903.13, indicating ₹124.66 - ₹903.13.
Is BIOCON undervalued or overvalued?
Based on our multi-method analysis, Biocon (BIOCON) appears to be trading above calculated value by approximately 56.9%.
BIOCON Financial Health — Key Ratios vs Industry Benchmarks
Biocon financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.33 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 2.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.29x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BIOCON Cash Flow Quality — Operating & Free Cash Flow
Biocon operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,994 Cr | ₹1,053 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹4,061 Cr | ₹3,960 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹2,954 Cr | ₹2,453 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,853 Cr | ₹-5,277 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹1,177 Cr | ₹346 Cr | Positive Free Cash Flow | 7/10 |